Dr. Jack West

Acquired Resistance to Targeted Therapies in Lung Cancer – How Do the Experts Approach It?

March 8th, 2013 - by Dr. Jack West

Here are a couple of great videos from several experts in lung cancer that describe their approach to the setting of acquired resistance, when a patient with a specific “targetable” mutation who responds well to the relevant treatment in question then develops progression of disease. ┬áThis is actually a pretty new challenge in lung cancer, and most experts feel that there’s reason to consider some newer approaches.

Dr. Greg Riely (Memorial Sloan-Kettering): How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?

Dr. Ravi Salgia (University of Chicago) on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse

Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)

I’ll add a post in the next few days that includes the answers of several experts to the question of what they think are the most promising new targeted therapies for lung cancer that we might actually see integrated as treatment options for patients in the next few years.

Share this:

Tags: , , , , , , , ,

Comments are closed.